Equities

Tauns Laboratories Inc

197A:TYO

Tauns Laboratories Inc

Actions
Health CareMedical Equipment and Services
  • Price (JPY)569.00
  • Today's Change-6.00 / -1.04%
  • Shares traded784.50k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Nov 15 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in JPY

The 3 analysts offering 12 month price targets for TAUNS Laboratories Inc have a median target of 750.00, with a high estimate of 890.00 and a low estimate of 520.00. The median estimate represents a 31.81% increase from the last price of 569.00.
High56.4%890.00
Med31.8%750.00
Low-8.6%520.00

Dividends

In 2024, Tauns Laboratories Inc reported a dividend of 10.65 JPY. The 3 analysts covering the company expect dividends of 30.58 JPY for the upcoming fiscal year, an increase of 187.16%.
Div growth (TTM)--
More ▼

Revenue history & estimates in JPY

TAUNS Laboratories Inc had 1st quarter 2025 revenues of 6.42m. This missed the 6.70m estimate of the one analyst following the company. The same period last year the company did not report revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.